sellWeak cluster of 410b5-1 plan
Garry E Menzel sold $32k of TCRR
President and CEO at TCR2 THERAPEUTICS INC.. 23,416 shares at an average of $1.36, traded Dec 5, 2022, filed Dec 7, 2022.
Warning score
30Value
$32k
23,416 shares
Holdings after
189,234
-11% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +25RoleCEO
- +5Trade size$32k at market
- +5Share of holdings soldSold 11% of holdings
- +15Cluster4 insiders selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0000899243-22-037941, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Dec 5, 2022 | SOpen-market sale Common Stock10b5-1 | -8,530 | $1.37 | $12k | 204,120 | Dec 7, 2022 |
| Dec 6, 2022 | SOpen-market sale Common Stock10b5-1 | -14,886 | $1.35 | $20k | 189,234 | Dec 7, 2022 |
Related signals
Other insiders at TCR2 THERAPEUTICS INC. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 31Weak | TCRRbuy TCR2 THERAPEUTICS INC. | Kevin C Tang owner | $86k 50,000 shares | +1% | |
| 36Weak | TCR2 THERAPEUTICS INC. | Mpm Asset Management LLC owner | $132k 70,170 shares | -19% | |
| 39Weak | TCR2 THERAPEUTICS INC. | Ansbert Gadicke director, owner | $132k 70,170 shares | -19% | |
| 31Weak | TCRRbuy TCR2 THERAPEUTICS INC. | Kevin C Tang owner | $88k 44,948 shares | +1% | |
| 33Weak | TCRRbuy TCR2 THERAPEUTICS INC. | Kevin C Tang owner | $164k 83,988 shares | +2% | |
| 39Weak | TCRRbuy TCR2 THERAPEUTICS INC. | Kevin C Tang owner | $548k 289,577 shares | +7% | |
| 15Weak | TCR2 THERAPEUTICS INC. | Alfonso Quintas Cardama Chief Medical Officer | $15k 13,799 shares | -11% | |
| 15Weak | TCR2 THERAPEUTICS INC. | Angela Justice Chief People Officer | $9,448 8,620 shares | -15% | |
| 31Weak | TCR2 THERAPEUTICS INC. | Garry E Menzel President and CEO | $35k 31,938 shares | -19% | |
| 15Weak | TCR2 THERAPEUTICS INC. | Peter Olagunju Chief Technical Officer | $5,299 4,830 shares | -17% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.